Expression of androgen receptor and Ki67 in cancer tissues of patients with triple-negative breast cancer and their relationship with prognosis / 中国综合临床

ABSTRACT

Objective:To investigate the expression of androgen receptor (AR) and Ki67 in cancer tissues of patients with triple-negative breast cancer (TNBC) and its relationship with prognosis.Methods:The clinical data of 41 patients with TNBC treated in Beijing Chuiyangliu Hospital from January 2010 to December 2017 were collected and analyzed retrospectively. In a retrospective case-control study, 186 patients with non TNBC diagnosed by surgery and pathology in Beijing Chuiyangliu Hospital in the same period were selected as the control group. The expression of AR and Ki67 in cancer tissues of the two groups was detected by immunohistochemical method. and the relationship between the different expression of AR and Ki67 and the clinicopathological features and prognosis of TNBC patients was analyzed. In the statistical analysis of this study, the measurement data with normal distribution were compared between the two groups by t-test. Chi square test was used for counting data. The survival rate was analyzed by Kaplan Meier method and compared between groups by long rank method.Results:The positive expression of AR in cancer tissues in TNBC group was lower than that in control group (46.3%(19/41) and 81.2%(151/186)) and the difference between the two groups was statistically significant (χ 2=21.69, P<0.001). The positive expression of Ki67 in TNBC group was higher than that in the control group (75.6%(31/41) and 58.6%(109/186)) and the difference between the two groups was statistically significant (χ 2=4.11, P=0.040). Among 41 patients with TNBC, there was no significant difference in age, menopausal status and tumor diameter between AR negative group and AR positive group (all P>0.05). There were significant differences in TNM stage, histological grade and lymph node metastasis between the two groups(χ 2 values were 9.34, 5.71 and 6.60, respectively; P values were <0.001, 0.020 and 0.010, respectively). Among 41 patients with TNBC, there was no significant difference in age, menopausal status, tumor diameter and histological grade between Ki67 negative group and Ki67 positive group (all P>0.05). There were significant differences in TNM stage and lymph node metastasis between the two groups (χ 2 values were 6.03 and 4.03; P values were 0.010 and 0.040). The 3-year disease-free survival rate of TNBC patients with AR positive expression was higher than that of patients with AR negative expression (80.1% and 67.2%), but there was no significant difference between them (χ 2=3.75, P=0.056). The 3-year survival rate of TNBC patients with AR positive expression was higher than that of patients with AR negative expression (94.1% and 78.0%), but there was no significant difference between the two groups (χ 2=3.35, P=0.068). The 3-year disease-free survival rate of TNBC patients with Ki67 positive expression was lower than that of patients with Ki67 negative expression (61.0% and 89.2%) (χ 2=6.53, P=0.038). The 3-year survival rate of TNBC patients with Ki67 positive expression was lower than that of patients with Ki67 negative expression (76.1% and 96.7%) (χ 2=4.01, P=0.045). Conclusion:Compared with non TNBC patients, the expression of AR decreased and the expression of Ki67 increased in TNBC patients. The higher the expression level of AR and the lower the positive expression of Ki67 in TNBC patients, the better prognosis. It can be used as an indicator to evaluate the prognosis of breast cancer patients.